Caracas, Feb 14 (Prensa Latina) The Cuban drug Heberprot-P benefits thousands of patients with diabetic foot ulcers in Venezuela, with a notable impact on the reduction of amputations, the expert Rafael Marcos Pimentel highlighted.
The coordinator of the Good Living Program for Diabetics made statements to Prensa Latina specifying that since August 18th, 2008, 253,419 patients have been treated, of which only 227 required radical surgery.
‘The over 99 percent efficiency in the use of recombinant human epidermal growth factor in patients with a satisfactory response to treatment reflects the positive impact of the project,’ Pimentel said.
Cuban specialist in angiology and vascular surgery Yailín Rios highlighted the benefits provided by the drug in extended consultations in the 23 states and the Capital District of Venezuela.
Over 50 percent of the people who go to Venezuela’s healthcare centers and emergency services with a diabetic foot ulcer end up with a major amputation; however, the need for this invasive procedure decreased exponentially with the use of the Heberprot-P, Rios explained.
As part of the actions of the program, Cuban angiologists and vascular surgeons advise and train Venezuelan colleagues through comprehensive care for patients with this disease.
Organized by the Ministry of Health of Venezuela, with the support of the Cuban Medical Mission, the Center for Genetic Engineering and Biotechnology and the Center of Immunotesting, both from Cuba, the Good Living Program for Diabetics program seeks the well-being of those affected with this pathology.